0001415889-24-018595.txt : 20240701
0001415889-24-018595.hdr.sgml : 20240701
20240701163802
ACCESSION NUMBER: 0001415889-24-018595
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240701
FILED AS OF DATE: 20240701
DATE AS OF CHANGE: 20240701
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Goldstein David M
CENTRAL INDEX KEY: 0001751719
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-42143
FILM NUMBER: 241091206
MAIL ADDRESS:
STREET 1: C/O ALUMIS INC.
STREET 2: 280 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER NAME:
FORMER CONFORMED NAME: Goldstein David
DATE OF NAME CHANGE: 20180830
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALUMIS INC.
CENTRAL INDEX KEY: 0001847367
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 280 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-231-6625
MAIL ADDRESS:
STREET 1: 280 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: ESKER THERAPEUTICS, INC.
DATE OF NAME CHANGE: 20230427
FORMER COMPANY:
FORMER CONFORMED NAME: FL2021-001, Inc.
DATE OF NAME CHANGE: 20210222
4
1
form4-07012024_080757.xml
X0508
4
2024-07-01
0001847367
ALUMIS INC.
ALMS
0001751719
Goldstein David M
C/O ALUMIS INC.
280 EAST GRAND AVENUE
SOUTH SAN FRANCISCO
CA
94080
false
true
false
false
Chief Scientific Officer
0
Class A Common Stock
2024-07-01
4
D
0
213903
D
0
I
By Trust
Common Stock
2024-07-01
4
A
0
213903
A
213903
I
By Trust
Class A Common Stock
2024-07-01
4
D
0
2994
D
0
I
By Family Members
Common Stock
2024-07-01
4
A
0
2994
A
2994
I
By Family Members
Stock Option (Right to Buy)
8.84
2024-07-01
4
D
0
42780
0
D
2032-01-26
Class A Common Stock
42780
0
D
Stock Option (Right to Buy)
8.84
2024-07-01
4
A
0
42780
0
A
2032-01-26
Common Stock
42780
42780
D
Stock Option (Right to Buy)
8.84
2024-07-01
4
D
0
171122
0
D
2032-01-26
Class A Common Stock
171122
0
D
Stock Option (Right to Buy)
8.84
2024-07-01
4
A
0
171122
0
A
2032-01-26
Common Stock
171122
171122
D
Stock Option (Right to Buy)
8.84
2024-07-01
4
D
0
11978
0
D
2033-06-22
Class A Common Stock
11978
0
D
Stock Option (Right to Buy)
8.84
2024-07-01
4
A
0
11978
0
A
2033-06-22
Common Stock
11978
11978
D
Stock Option (Right to Buy)
8.84
2024-07-01
4
D
0
30642
0
D
2033-10-08
Class A Common Stock
30642
0
D
Stock Option (Right to Buy)
8.84
2024-07-01
4
A
0
30642
0
A
2033-10-08
Common Stock
30642
30642
D
Stock Option (Right to Buy)
10.2
2024-07-01
4
D
0
206074
0
D
2034-05-05
Class A Common Stock
206074
0
D
Stock Option (Right to Buy)
10.2
2024-07-01
4
A
0
206074
0
A
2034-05-05
Common Stock
206074
206074
D
Stock Option (Right to Buy)
13.33
2024-07-01
4
D
0
53475
0
D
2034-06-05
Class A Common Stock
53475
0
D
Stock Option (Right to Buy)
13.33
2024-07-01
4
A
0
53475
0
A
2034-06-05
Common Stock
53475
53475
D
Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock.
Shares are held directly by the Baily Goldstein Living Trust dated March 4, 2014, for which the Reporting Person serves as a trustee.
Shares are held directly by family members of Reporting Person residing in his primary residence.
25% of the shares underlying this option vested on January 27, 2023, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
33% of the shares underlying this option vested on January 27, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 48 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
25% of the shares underlying this option vested on May 22, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
25% of the shares underlying this option vest on October 9, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
The option vests in three equal installments, subject to the Issuer's satisfaction of certain performance criteria on each of May 6, 2028, May 6, 2029 and May 6, 2030, and subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date.
25% of the shares underlying this option vest on June 6, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date.
/s/ Sara Klein, Attorney-in-Fact
2024-07-03